Tinzaparin
- Generic Name
- Tinzaparin
- Brand Names
- Innohep
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9041-08-1
- Unique Ingredient Identifier
- 7UQ7X4Y489
- Background
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III...
- Indication
Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing c...
- Associated Conditions
- Clotting, Deep Vein Thrombosis, Pulmonary embolism, Deep vein thrombosis, Venous Thromboembolism
- Associated Therapies
- -
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 6660
- Registration Number
- NCT05735639
- Locations
- 🇬🇧
Imperial College Hospital NHS Foundation Trust, London, United Kingdom
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Galician Research Group on Digestive Tumors
- Target Recruit Count
- 526
- Registration Number
- NCT05625932
- Locations
- 🇪🇸
Hospital Universitario De Móstoles, Móstoles, Madrid, Spain
🇪🇸Hospital Universitario Son Espases, Palma De Mallorca, Baleares, Spain
🇪🇸Hospital Universitario Príncipe de Asturias (HUPA) de Alcalá de Henares, Alcalá De Henares, Madrid, Spain
The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Michalis Karamouzis
- Target Recruit Count
- 450
- Registration Number
- NCT05178628
- Locations
- 🇬🇷
Institute of Molecular Medicine and Biomedical Research, Athens, Attiki, Greece
🇬🇷Eygenideio Hospital, Oncology Department, Athens, Attiki, Greece
Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- University Hospital of Patras
- Target Recruit Count
- 300
- Registration Number
- NCT05036824
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Epirus, Greece
🇬🇷General Hospital of Kerkira "Ag. Irini", Korfu, Ionian Islands, Greece
🇬🇷Evangelismos General Hospital, Athens, Attica, Greece
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 9
- Registration Number
- NCT04794569
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada
Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis
- Conditions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 12
- Registration Number
- NCT04741464
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Hospital Universitario Infanta Leonor
- Target Recruit Count
- 311
- Registration Number
- NCT04730856
- Locations
- 🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸Hospital Virgen de la Luz, Cuenca, Spain
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 99
- Registration Number
- NCT03240120
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 420
- Registration Number
- NCT03099031
- Locations
- 🇫🇷
George Pompidou European Hospital, Paris, France
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 59
- Registration Number
- NCT03090880
- Locations
- 🇫🇷
Hôpital Pontchaillou, Rennes, Bretagne, France
🇫🇷Centre Hospitalier régional d'Orléans, Orléans, Centre, France
🇫🇷Centre Oscar Lambret, Lille, Hauts De France, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.